GlycoNex initiates first-in-human Phase I trial of its glycan-targeted ADC GNX1021 in Japan
Executive summary: GlycoNex dosed the first patient in a Phase I clinical trial of GNX1021, its glycan‑directed antibody‑drug conjugate, in Japan. This advances GlycoNex’s pipeline into clinical stages, validates a novel glycan‑targeting ADC approach, and signals potential new oncology therapeutic options.
Who is involved: GlycoNex Inc. (TPEx: 4168), the clinical trial site in Japan, and regulators such as Japan’s PMDA overseeing the IND.
Likely next: Completion of Phase I dose‑escalation, interim safety readout, and planning for Phase II expansion or partnership talks.
On August 3 2026, GlycoNex announced dosing of the first patient in a Phase I study of GNX1021, a novel antibody-drug conjugate directed against specific glycans, conducted in Japan. The trial marks the company's transition from preclinical to clinical development of its ADC platform. Safety and pharmacokinetics will be evaluated per the study protocol. Successful completion could enable further dose‑expansion studies and potential partnership discussions.
Timeline
- — GlycoNex Doses First Patient in Phase I Trial of GNX1021, Advancing Its Glycan-Directed ADC into Clinical Development (PR Newswire)
Analysis — what this means
Sectors affected
- Biotechnology
- Antibody-drug conjugate (ADC) oncology
Regulatory implications
- Must comply with PMDA Phase I IND requirements
- Adverse event reporting per ICH E2A guidelines
Historical parallels
- First-in-human ADC trial of Brentuximab vedotin (Adcetris) 2011
- Approval of trastuzumab emtansine (Kadcyla) 2013
Key entities
Sources
- GlycoNex Doses First Patient in Phase I Trial of GNX1021, Advancing Its Glycan-Directed ADC into Clinical Development — PR Newswire
Related cases
- Akeso’s 2026 interim results show record‑high drug sales and progress on its IO 2.0 strategy, advancing bispecific ADCs in oncology, immunology and Alzheimer’s
- Akeso's B7‑H3 ADC AK157D1 gains Phase I clearance, adding a third differentiated candidate to its oncology pipeline
- Henlius and Sandoz partner to co‑develop up to ten biosimilar mAb and ADC assets, aiming to accelerate global market access and revenue generation
- Akeso advances its IO2.0/ADC2.0 strategy with first patient dosed in Phase II trial of AK146D1 combined with ivonescimab for breast cancer
- Akeso initiates first‑in‑human trial of its HER3‑targeted ADC combined with Ivonescimab in lung cancer, advancing its IO2.0+ADC2.0 pipeline
- Mabwell's ESMO 2026 oral presentation of clinical data for its Nectin-4-targeting ADC 9MW2821 highlights potential progress in triple-negative breast cancer therapy and could affect oncology investment sentiment